Biopôle Clermont-Limagne
Technology park for life sciences
Year of creation : 2017
Statut : simplified joint stock company
Size : 7
% of CA dedicated to R&D : 100
Patents (number of) : 0

Contact details

Biopôle Clermont-Limagne

5 rue Emile Duclaux

63360 Saint-Beauzire

Contact : Thierry BERNARDI
Phone : +33 473 333 980
Email :
Website :

BioFilm Pharma

The next generation of AntiMicrobials must be AntiBiofilms

BioFilm Pharma brings its innovative approach by addressing the chronic disease and long-term treatment of “diabete foot ulcers” (15 million new patients each year), which represent a heavy cost for Health Care system in high-income countries (4 billions €). BioFilm Pharma holds the unique proprietary technology to develop first-in-class products able to prevent and cure the metastatic bacterial infections named biofilms considered as the new paradigm in the antibiotherapy. We have already 5 compounds in our pipeline and are 3 years up to proof-of-concept in patients for potential blockbusters. We have already 2,4 M€ secured by a syndicate of historic investors or grants and we are looking for 20 M€ funds to engage CMC, preclinical and clinical studies.